Diflucan & Lyme

Somewhere I vaguely remember that Diflucan is affective against Lyme or if it is combined with something else that it is. Is this true or am I dreaming?

Thank you for the detailed and helpful information. Perhaps this is why Diflucan has helped me. Here I thought it was just fighting the yeast when in fact it works against Lyme. Incidentally, I am back on Diflucan again and seeing some improvements.

According to the Marshall Protocol
folks, the -azole meds like Diflucan
also disrupt the metabolism of vitamin
D, and vitamin D is something the Lyme
bacteria use to thrive.

It seems I have Lyme, and in the past
I've tried Diflucan for over a month,
and can say it did reduce my symptoms,
but was not a cure for me.


Yes, diflucan is usually prescribed for yeast infections, however,
there's good evidence to suggest that borrelia are also vulnerable to
P450 inhibitors. Borrelia have only 1 P450 homologue enzyme,
putidaredoxin (PdR), and that would make it extremely susceptible to
an inhibitor of that enzyme. Fluconazole may just be that inhibitoThe breakthrough discovery
made by Dr. Schardt that borrelia are susceptible to fluconazole.

To date, in over 60 patients, Dr. Schardt is noting a 90% remission
rate using fluconazole. From past cases, we have been gathering
some significant anecdotal evidence that fluconazole therapy has
been helping cases of neuroborreliosis.
Clinical effects of fluconazole in patients with neuroborreliosis.

Schardt FW.

Betriebsarztliche Untersuchungsstelle, Bayerische Julius-Maximilians-
Universitat, Wurzburg, Germany. Fritz.Schardt@m...

Eleven patients with neuro-borreliosis had been treated with 200 mg
fluconazole daily for 25 days after an unsuccessful therapy with
antibiotics. At the end of treatment eight patients had no
borreliosis symptoms and remained free of relapse in a follow-up
examination one year later. In the remaining four patients, symptoms
were considerably improved. At the end of therapy immune reactivity
(IgM+) disappeared in three patients. Since borrelia spp. are almost
exclusively localised intracellular, they may depend on certain
metabolites of their eucaryotic host cell. Inhibition of P450 and
other cytochromes by fluconazole may incapacitate Borrelia upon
longterm exposure.

PMID: 15337633 [PubMed - in process]

You may find this info useful ..Zith is effective against spirochetes [as syphilis] & when used in combo with other drugs assumes Antifungal properties ..PaulNew syphilis med shows potential


Hi Paul,

What drugs combine with Zithromax to become anti-fungal? Is it Ibuprofen?

Do you have an article or link for it?


Try this Grace ,

Looking at the synergy to be gained from using various drug combos , I found some very enlightening extracts quoting azithromycin combos �They highlight the Antifungal properties of the drug �It could explain the unexpected reactions to the drug�.
The second extract found Azithromycin demonstrated no activity against Fusarium when tested alone but when combined with amphotericin B the killing power of the combo increased dramatically.
The last extract explores the Antifungal effects of what is considered non Antifungal drugs �The is clear � tap into the enhanced killing power and broader spectrum of combination drug treatment. .Paul�
�
Expert Opin Pharmacother. 2002 Nov;3(11):1541-2.

Babesiosis in humans: a treatment review.

Weiss LM.

Division of Infectious Diseases, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Room 504 Forchheimer Building, Bronx, New York, 10461, USA. lmweiss@aecom.yu.edu

Human infections with Babesia species, in particular Babesia microti, are tick-borne illnesses that are being recognised with increased frequency. Coinfection with ehrlichiosis and Lyme disease is also being recognised as an important feature of these tick-borne illnesses. Despite the superficial resemblance of Babesia to malaria, these piroplasms do not respond to chloroquine or other similar drugs. However, the treatment of babesiosis using a clindamycin-quinine combination has been successful. Data in animal models and case-reports in humans have suggested that an atovaquone-azithromycin combination is also effective. This was confirmed in a recent prospective, open, randomised trial of clindamycin-quinine versus azithromycin-atovaquone. This paper reviews the literature on the treatment of human babesiosis and the animal models of these human pathogens.

Publication Types:
� Review
� Review, Academic

PMID: 12150690 [PubMed - indexed for MEDLINE] J Antimicrob Chemother. 1998 Jan;41(1):127-30. Related Articles, Links

The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis.

Clancy CJ, Nguyen MH.

Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA.

We investigated the interaction between amphotericin B and azithromycin in vitro against 26 clinical isolates of Fusarium. Synergy was demonstrated in all isolates. Amphotericin B MICs were reduced from a mean of 1 mg/L when tested alone to a mean of 0.37 mg/L when tested in combination with azithromycin. Azithromycin demonstrated no activity against Fusarium when tested alone (MIC > 128 mg/L). When combined with amphotericin B the mean MIC was reduced to 5.5 mg/L, a level readily achieved in tissue. Given the resistance of Fusarium to conventional therapy, the in-vitro synergy between amphotericin B and azithromycin might prove to be important in therapy for fusariosis.

PMID: 9511049 [PubMed - indexed for MEDLINE]
Article
European Journal of Clinical Microbiology & Infectious Diseases Publisher: Springer-Verlag Heidelberg ISSN: 0934-9723 (Paper) 1435-4373 (Online) DOI: 10.1007/s10096-003-0947-x Issue: Volume 22, Number 7 July 2003 Pages: 397 - 407
ReviewAntifungal Activity of Nonantifungal DrugsJ. Afeltra1, 2 and P. E. Verweij1, 2 (1) Department of Medical Microbiology, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
(2) Nijmegen University Center for Infectious Diseases, Nijmegen, The Netherlands
Published online: 26 June 2003Abstract The antifungal activity of synthetic, nonchemotherapeutic compounds, antineoplastic agents and antibacterial drugs, such as sulphonamides, has been known since the early 20th century (1932). In this context, the term "nonantifungal" is taken to include a variety of compounds that are employed in the management of pathological conditions of nonfungal infectious etiology but have been shown to exhibit broad-spectrum antifungal activity. In this review, the antifungal properties of compounds such as chlorpromazine, proton pump inhibitors, antiarrhythmic agents, cholesterol-lowering agents, antineoplastic and immunosuppressive agents, antiparasitic drugs and antibiotics are described. Since fungi are eukaryotic cells, they share many pathways with human cells, thus increasing the probability of antifungal activity of "nonfungal drugs". The potential of these drugs for treatment of fungal infections has been investigated sporadically using the drugs alone or in combination with "classic" antifungal agents. A review of the literature, supplemented with a number of more recent investigations, suggests that some of these compounds enhance the activity of conventional antifungal agents, eliminate natural resistance to specific antifungal drugs (reversal of resistance) or exhibit strong activity against certain fungal strains in vitro and in animal models. The role of these agents in the epidemiology and in the clinical manifestations of fungal infections and the potential of certain drugs for treatment of invasive fungal infections require further investigation. P. E. VerweijEmail: p.verweij@mmb.umcn.nlPhone: +31-24-3614356Fax: +31-24-3540216


I read somewhere that it is used for Lyme.